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Image registration accuracy was<2mm for all anatomic head and neck 
landmark displacements in the x, y and z direction relative to CT.  
Image quality was found to be comparable to the commissioning 
benchmark. SNR data for T1 FSE and T2 FSE were not statically 
significantly different (p= 0.53, 0.10) from benchmark dataset. 
However, the benchmark configuration appears to provide more 
optimized signal across all anatomical structures. For superficial 
structures closer to the surface, e.g. parotid, the RT coil provides 
very high signal due to closer proximity of the coil (T1 FSE mean RT 
126.1 v diagnostic 99.8). For deeper structures the converse is true, 
e.g. brainstem (mean SNR RT 33.7 v diagnostic 58.2).  
Conclusions: Benchmarking of the system and clinical process has 
allowed for the development of an MR-SIM quality assurance program 
for this anatomical site, with well defined imaging and image 
registration metrics.  
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Purpose/Objective: The dose-volume effect of radiation on breast 
tissue is poorly understood with few attempts at modeling the Normal 
Tissue Complication Probability (NTCP). This study estimates the NTCP 
parameter values for breast fibrosis after external beam breast 
radiation therapy (RT).  
Materials and Methods: Individual patient data of 5282 patients from 
the multi-centre EORTC 22881-10882 'boost versus no boost' trial and 
574 patients from the Cambridge breast IMRT trial were pooled and 
analysed. All patients received whole breast irradiation (WBI) (40Gy in 
15 fractions over 3 weeks or 50Gy in 25 fractions over 5 weeks) 
followed by tumour bed (TB) boost in some cases. A two compartment 
dose volume histogram (DVH) model was used with TB volume 
receiving WBI plus boost dose as the first compartment and whole 
breast volume outside the TB volume receiving WBI dose alone as 
second compartment. Two NTCP models were considered: (a) Lyman 
Kutcher Burman (LKB) model and (b) Niemierko model. The model 
parameters (BEUD50, m or γ50 and n)) for moderate-severe breast 
fibrosis were estimated using the Maximum Likelihood Estimation 
(MLE) method. To account for hypofractionation, a biologically 
equivalent dose (BED3) was generated using α/β of 3Gy. The 
parameter 95% confidence intervals (CI) were generated using the 
Profile Likelihood Estimation method. Summary data from the START 
pilot trial (n=1410) were used to asses the goodness of fit of the 
predicted NTCP model using the Pearson chi-square test. 
Results: One hundred and fifty four patients (26.8%) in the Cambridge 
trial and one thousand and ninety six patients (20.7%) in the EORTC 
trial developed moderate-severe breast fibrosis. Using the MLE 
method, the best estimated NTCP parameters were BEUD3(50) 
=136.4Gy, γ50=0.9 and n=0.011 for the Niemierko model and 
BEUD3(50) =132Gy, m=0.35 and n=0.012 for the LKB model. A small 
value of volume parameter 'n' suggests that for moderate-severe 
fibrosis, breast tissue is a serial organ. The observed rates of 
moderate-severe fibrosis in the START pilot trial were in good 
agreement to the predicted rates from the above models (χ2=0.05; 
p=0.95 with five degrees of freedom) Figure 1. 
 
 
Conclusions: This large multi-centre pooled study indicates that the 
effect of volume parameter is small and the maximum radiotherapy 
dose is the most important parameter to influence late breast fibrosis. 
Clinical validation of these results from future prospective studies is 
suggested. 
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Purpose/Objective: Breast cancer is the most commonly diagnosed 
female cancer, and with good survival rates, it is imperative that any 
potential long term side effects from this effective treatment are 
reduced. Techniques specific to patient cohorts with differing local 
recurrence risk factors are likely to be the new standard of care in 
breast radiotherapy in 5 to 10 years. These techniques include 
simultaneous integrated boost (SIB) and conformal non co-planar 
beam arrangements for accelerated partial breast irradiation (APBI). 
These beam arrangements distribute the dose throughout the body in 
a different pattern to the standard treatment. This work reports a 
comparison of the risk for these modern radiotherapy techniques, 
including the use of image guidance.  
Materials and Methods: Five treatment plans were created on a 
patient CT scan: standard whole breast treatment (WBRT), conformal 
non co-planar five field plan for an APBI treatment, two volume/two 
dose level SIB plan with 5 fields, three volume/three dose level SIB 
plan with 7 fields (forward planned), three volume/three dose level 
SIB plan with 7 fields (inverse planned). The plans were transferred to 
a whole body phantom. Regions in the phantom which represented 
radiosensitive organs were delineated and thermoluminescent 
dosimeters (TLD) used to measure the dose. Dose from a breast 
imaging kilovoltage cone beam CT protocol was measured with TLD in 
the same regions. These dose data were used as input into the 
Biological Effects of Ionising Radiation Report VII models of second 
cancer induction and lifetime risks calculated for the five treatment 
classes and intensive imaging regimes. 
Results: The lifetime risk data showed that complex radiotherapy 
techniques did not increase the theoretical risk of second cancer 
incidence for organs distant from the treated breast, or the 
contralateral breast where appropriate constraints were applied. SIB 
treatments were predicted to increase the lifetime risk of second 
cancer incidence in the lungs compared to standard breast 
radiotherapy; this was outweighed by the threefold reduction in 5 yr 
local recurrence risk with adjuvant radiotherapy for a high risk cohort 
for whom these treatments are appropriate. A lower lifetime risk of 
second cancer in the contralateral breast was predicted for the APBI 
method, compared with WBRT. The contribution of imaging dose to 
the total dose from both treatment and imaging did not exceed 22% 
for any measured organ. 
Conclusions: Modern complex radiotherapy techniques used in breast 
cancer were not predicted to increase the theoretical risk of second 
cancer incidence in organs far from the treated breast. Where 
increases in the lifetime risk of induced second cancer were 
predicted, these remained small compared to the large reduction in 
local recurrence risk from receiving RT as a component of treatment. 
